Mark Curran PhD

Dr. Curran is currently Vice President of Immunology Systems Pharmacology and Biomarkers at Janssen Research & Development, LLC. His team is responsible for biomarker strategy, implementation, analysis and interpretation for all assets in the immunology portfolio. The team enjoys robust collaborations with Discovery R&D to define potential new targets and pathways through multi-scale systems biology and is responsible for development and commercialization of companion diagnostics (Co-Dx). Dr. Curran’s drug development experience includes six years with Janssen R&D and five years at Bristol Myers-Squibb. Mark has held various positions including directing biomarker efforts for the immunology, neuroscience, and CV/Met Therapeutic Areas (TAs). He was also an Early Development Team (EDT) leader responsible for clinical development and proof of concept (POC) for multiple small molecule compounds in immunology. Prior to joining the pharmaceutical industry, Mark gained valuable experience at several smaller companies with focus on genomics, diagnostics and early drug discovery. Mark earned his doctorate in human genetics at the University of Utah, has authored over 40 scientific publications and holds multiple patents. He has contributed seminal discoveries in the field of heritable cardiac arrhythmias and developed the Familion™ diagnostic test for long QT syndrome. He has also contributed findings on heritable vascular disease, defined novel ion channel drug targets, and genetics of autoimmune disease.